Cerebral vascular leak in a mouse model of amyloid neuropathology

Journal of Cerebral Blood Flow and Metabolism

Volumn 34, Issue 10, 2014, Pages 1646-1654

  Tanifum, Eric A ^a   Starosolski, Zbigniew A ^a,b   Fowler, Stephanie W ^c   Jankowsky, Joanna L ^c   Annapragada, Ananth V ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b SILESIAN UNIVERSITY OF TECHNOLOGY   (Poland)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; amyloid deposition; blood brain barrier; cerebral amyloid angiopathy; computed tomography; imaging; nanoparticle; vascular leak

Indexed keywords

AMYLOID PROTEIN; IODIXANOL; NANOPARTICLE; AMYLOID; AMYLOID PRECURSOR PROTEIN; CONTRAST MEDIUM;

AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CEREBROVASCULAR DISEASE; CEREBROVASCULAR LEAK; CHOROID PLEXUS; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; GENOTYPE; HISTOPATHOLOGY; MOLECULAR PROBE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VASCULAR AMYLOIDOSIS; ANIMAL; BLOOD BRAIN BARRIER; BRAIN; BRAIN ARTERY; DIAGNOSTIC USE; DISEASE MODEL; FEMALE; GENETICS; HUMAN; MALE; PATHOLOGY; TRANSGENIC MOUSE; VASCULARIZATION;

AMYLOID; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CEREBRAL AMYLOID ANGIOPATHY; CEREBRAL ARTERIES; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MICE; MICE, TRANSGENIC; NANOPARTICLES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84921734855     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2014.125     Document Type: Article

References (41)

1. Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrife Psychiatrie 1907; 64: 146-148.
2. Kalaria RN. Cerebrovascular degeneration is related to amyloid-b protein deposition in Alzheimer's disease. Ann NY Acad Sci 1997; 826(1 Cerebrovascul): 263-271.
3. Pettersen JA, Sathiyamoorthy G, Gao F-Q, Szilagyi G, Nadkarni St NK, George-Hyslop P et al. Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook dementia study. Arch Neurol 2008; 65: 790-795.
4. Skoog I, Wallin A, Fredman P, Hesse C, Aevarsson O, Karlsson I et al. A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia. Neurology 1998; 50: 966-971.
5. Cordonnier C, van der Flier WM. Brain microbleeds and Alzheimer's disease: innocent observation or key player? Brain 2011; 134: 335-344.
6. Thijs V. Cerebral microbleeds: important or not important? Swiss Arch Neurol Psychiatry 2011; 162: 290-292.
7. van der Vlies AE, Goos JDC, Barkhof F, Scheltens P, van der Flier WM. Microbleeds do not affect rate of cognitive decline in Alzheimer disease. Neurology 2012; 79: 763-769.
8. Thakker DR, Weatherspoon MR, Harrison J, Keene TE, Lane DS, Kaemmerer WF et al. Intracerebroventricular amyloid-antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice. Proc Natl Acad Sci USA 2009; 106: 4501-4506.
9. Vernooij MW, van der Lugt A, Ikram MA, Wielopolski PA, Niessen WJ, Hofman A et al. Prevalence and risk factors of cerebral microbleeds: the Rotterdam Scan Study. Neurology 2008; 70: 1208-1214.
10. Koennecke H-C. Cerebral microbleeds on MRI: prevalence, associations, and potential clinical implications. Neurology 2006; 66: 165-171.
11. Viswanathan A, Chabriat H. Cerebral microhemorrhage. Stroke 2006; 37: 550-555.
12. Perlmutter LS, Chui HC. Microangiopathy, the vascular basement membrane and Alzheimer's disease: a review. Brain Res Bull 1990; 24: 677-686.
13. Cullen KM, Kó csi Z, Stone J. Microvascular pathology in the aging human brain: evidence that senile plaques are sites of microhaemorrhages. Neurobiol Aging 2006; 27: 1786-1796.
14. Zipser BD, Johanson CE, Gonzalez L, Berzin TM, Tavares R, Hulette CM et al. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging 2007; 28: 977-986.
15. Blanc EM, Toborek M, Mark RJ, Hennig B, Mattson MP. Amyloid b-peptide induces cell monolayer albumin permeability, impairs glucose transport, and induces apoptosis in vascular endothelial cells. J Neurochem 1997; 68: 1870-1881.
16. Ujiie M, Dickstein DL, Carlow DA, Jefferies WA. Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation 2003; 10: 463-470.
17. Dickstein DL, Walsh J, Brautigam H, Stockton Jr. SD, Gandy S, Hof PR. Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. Mt Sinai J Med 2010; 77: 82-102.
18. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 2011; 12: 723-738.
19. Zlokovic BV. Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease. JAMA Neurol 2013; 70: 440-444.
20. Tanifum EA, Dasgupta I, Srivastava M, Bhavane RC, Sun L, Berridge J et al. Intravenous delivery of targeted liposomes to amyloid-b pathology in APP/PSEN1 transgenic mice. PLoS ONE 2012; 7: e48515.
21. Wadghiri YZ, Li J, Wang J, Hoang DM, Sun Y, Xu H et al. Detection of amyloid plaques targeted by bifunctional USPIO in Alzheimer's disease transgenic mice using magnetic resonance microimaging. PLoS ONE 2013; 8: e57097.
22. Yang J, Wadghiri YZ, Hoang DM, Tsui W, Sun Y, Chung E et al. Detection of amyloid plaques targeted by USPIO-Ab1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging. Neuroimage 2011; 55: 1600-1609.
23. Andrieux K, Couvreur P. Nanomedicine as a promising approach for the treatment and diagnosis of brain diseases: the example of Alzheimer's disease. Ann Pharm Fr 2013; 71: 225-233.
24. LaRue B, Hogg E, Sagare A, Jovanovic S, Maness L, Maurer C et al. Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg2576 mice. J Neurosci Methods 2004; 138: 233-242.
25. Starr JM, Farrall AJ, Armitage P, McGurn B, Wardlaw J. Blood-brain barrier permeability in Alzheimer's disease: a case-control MRI study. Psychiatry Res 2009; 171: 232-241.
26. Kao C-Y, Hoffman EA, Beck KC, Bellamkonda RV, Annapragada AV. Long-residence-time nano-scale liposomal iohexol for X-ray-based blood pool imaging. Acad Radiol 2003; 10: 475-483.
27. Mukundan S, Ghaghada KB, Badea CT, Kao C-Y, Hedlund LW, Provenzale JM et al. A liposomal nanoscale contrast agent for preclinical CT in mice. AJR Am J Roentgenol 2006; 186: 300-307.
28. Karathanasis E, Suryanarayanan S, Balusu SR, McNeeley K, Sechopoulos I, Karellas A et al. Imaging nanoprobe for prediction of outcome of nanoparticle chemotherapy by using mammography. Radiology 2009; 250: 398-406.
29. Annapragada AV, Hoffman E, Divekar A, Karathanasis E, Ghaghada KB. Highresolution CT vascular imaging using blood pool contrast agents. Methodist Debakey Cardiovasc J 2012; 8: 18-22.
30. Jankowsky JL, Slunt HH, Gonzales V, Savonenko AV, Wen JC, Jenkins NA et al. Persistent amyloidosis following suppression of Ab production in a transgenic model of Alzheimer disease. PLoS Med 2005; 2: e355.
31. Rotenberg A, Mayford M, Hawkins RD, Kandel ER, Muller RU. Mice expressing activated CaMKII lack low frequency LTP and do not form stable place cells in the CA1 region of the hippocampus. Cell 1996; 87: 1351-1361.
32. Rodgers SP, Born HA, Das P, Jankowsky JL. Transgenic APP expression during postnatal development causes persistent locomotor hyperactivity in the adult. Mol Neurodegener 2012; 7: 28.
33. Lu H, Hsiao T, Li X, Liang Z. Noise properties of low-dose CT projections and noise treatment by scale transformations. IEEE Nuclear Sci Symp Conf 2001; 3: 1662-1666.
34. Kittler J, Illingworth J. Minimum error thresholding. Pattern Recogn 1986; 19: 41-47.
35. Franklin K, Paxinos G. The mouse brain in stereotaxic coordinates (3rd ed) with CD-ROM. Librairie Lavoisier: Cachan, France, 2007.
36. Dhenain M, Tannir El Tayara El N, Wu T-D, Guégan M, Volk A, Quintana C et al. Characterization of in vivo MRI detectable thalamic amyloid plaques from APP/PS1 mice. Neurobiol Aging 2009; 30: 41-53.
37. Wang A, Das P, Switzer RC, Golde TE, Jankowsky JL. Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-immunotherapy. J Neurosci 2011; 31: 4124-4136.
38. Ayyagari AL, Zhang X, Ghaghada KB, Annapragada A, Hu X, Bellamkonda RV. Long-circulating liposomal contrast agents for magnetic resonance imaging. Magn Reson Med 2006; 55: 1023-1029.
39. Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M et al. Sleep drives metabolite clearance from the adult brain. Science 2013; 342: 373-377.
40. Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid b. Sci Transl Med [Internet] 2012; 4: 147ra111-1. Available from http://eutils. ncbi. nlm. nih. gov/entrez/eutils/elink. fcgi? dbfrom=pubmed&id=22896675&retmode=ref&cmd=prlinks.
41. Iliff JJ, Lee H, Yu M, Feng T, Logan J, Nedergaard M et al. Brain-wide pathway for waste clearance captured by contrast-enhanced MRI. J Clin Invest 2013; 123: 1299-1309.